University of Florida

Summary

University of Florida is a medical facility located in Jacksonville, Florida. This center is recognized for care of Coronary Artery Disease, Heart Failure, Stroke, Cardiovascular Disease, I Am A Healthy Volunteer and other specialties. University of Florida is involved with conducting 218 clinical trials across 470 conditions. There are 25 research doctors associated with this hospital, such as Mehdi Mirsaeidi, MD, Carmen Isache, MD, Tung Wynn, MD, and Daniel Soffer, MD.

Top PIs

Clinical Trials running at University of Florida

Coronary Artery Disease

Stroke

Heart Failure

Cancer

Epilepsy

Retinitis Pigmentosa

Prostate Cancer

Retinal Disease

Retinal Degeneration

Retinal Dystrophy

Prasugrel + Clopidogrel

for Coronary Artery Disease

The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.

Recruiting

3 awards

Phase 4

2 criteria

Antiplatelet Therapy Strategies

for Coronary Artery Disease

Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant increase in bleeding events. Over time, different DAPT de-escalation strategies have been developed to reduce the bleeding risk while maintaining the ischemic protection, but there is currently no head-to-head comparison between them. The purpose of this clinical trial is to conduct a head-to-head comparison on the pharmacodynamic efficacy of DAPT de-escalation by dose reduction to low-dose prasugrel (5 mg od) and DAPT de-escation by switching from standard-dose more potent P2Y12 receptor inhibitor to standard-dose clopidogrel (75 mg). To determine if the PD profiles of these two strategies are comparable, we aim to conduct a non-inferiority study.

Recruiting

3 awards

Phase 4

1 criteria

Antiplatelet Therapy

for Coronary Artery Disease

Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e., switching from prasugrel or ticagrelor to clopidogrel while maintaining aspirin) and b) potent P2Y12 inhibitor monotherapy (i.e., maintaining prasugrel or ticagrelor and dropping aspirin). These strategies have been tested in a number of trials and have led to changes in practice guidelines to consider either one of these strategies as bleeding reduction approaches among ACS patients undergoing PCI. However, comparative assessments between DAPT de-escalation and potent P2Y12 inhibitor monotherapy are lacking.

Recruiting

3 awards

Phase 4

4 criteria